ANI's Fluoxetine Oral Solution is the generic version of the Reference Listed Drug Prozac.
The current annual US market for Fluoxetine Oral Solution is approximately USD 14.6m, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
ANI Pharmaceuticals is a bio-pharmaceutical company engaged in developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
Its team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities.
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition